A multicentric randomized phase II clinical trial evaluating high-dose thiotepa as adjuvant treatment to standard chemotherapy in patients with resectable relapsed osteosarcoma

The role of high-dose chemotherapy in relapsing osteosarcomas has not been established. We evaluated the efficacy and tolerance of high-dose thiotepa (HDTp) after standard chemotherapy (SCT) in patients with relapsed osteosarcoma.

Source: European Journal of Cancer - December 11, 2019 Category: Cancer & Oncology Authors: Perrine Marec-Berard, C écile Dalban, Nathalie Gaspar, Laurence Brugieres, Jean-Claude Gentet, Cyril Lervat, Nadège Corradini, Marie-Pierre Castex, Claudine Schmitt, Hélène Pacquement, Marie-Dominique Tabone, Mehdi Brahmi, Séverine Metzger, Jean-Yves Tags: Original Research Source Type: research